The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL OMB 3235-Number: 0076 Estimated average burden hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names X	None	Entity Type
<u>0001797768</u>	Indiffes		V. Corporation
Name of Issuer			X Corporation Limited Partnership
Kinnate Biopharma Inc.			Limited Liability Company
Jurisdiction of			General Partnership
Incorporation/Organization			Business Trust
DELAWARE			Other (Specify)
Year of Incorporation/Orga	nization		
Over Five Years Ago			
X Within Last Five Years (Specify Ye	ear) 2018		
Yet to Be Formed			
2. Principal Place of Business and Con	tact Information		
Name of Issuer			
Kinnate Biopharma Inc.			
Street Address 1		Stre	et Address 2
11975 EL CAMINO REAL, STE 101			
5	Province/Country	ZIP/PostalCode	Phone Number of Issuer
SAN DIEGO CALIFO	ORNIA 9	92130	8582994699
3. Related Persons			
Last Name	First N	lame	Middle Name
Kaldor	Stephen	W.	
Street Address 1 11975 El Camino Real, Ste 101	Street Ad	dress 2	
City	State/Provinc	ce/Country	ZIP/PostalCode
San Diego	CALIFORNIA	9213 ⁻	
Relationship: Executive Officer X	Director X Promoter		
Clarification of Response (if Necessary	y):		
Last Name	First N	Jame	Middle Name
Farzan	Nima	W.	
Street Address 1	Street Ad	ldress 2	
11975 El Camino Real, Ste 101			
City	State/Provinc	ce/Country	ZIP/PostalCode
San Diego	CALIFORNIA	9213	0
Relationship: X Executive Officer X	Director Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Tananbaum	Jim	
Street Address 1	Street Address 2	
11975 El Camino Real, Ste 101		
City	State/Province/Country CALIFORNIA	ZIP/PostalCode 92130
San Diego Balationshine Executive Officer N		52150
Relationship: Executive Officer 2	C Director Promoter	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Gordon	Carl	W.
Street Address 1	Street Address 2	
11975 El Camino Real, Ste 101		
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92130
Relationship: Executive Officer 2	K Director Promoter	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Rome	Michael	W.
Street Address 1	Street Address 2	
11975 El Camino Real, Ste 101		
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92130
Relationship: Executive Officer 2	K Director Promoter	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Meltz	Mark	
Street Address 1	Street Address 2	
11975 El Camino Real, Ste 101		
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92130
Relationship: X Executive Officer	Director Promoter	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Flaherty	Keith	
Street Address 1	Street Address 2	
11975 El Camino Real, Ste 101		
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92130
Relationship: Executive Officer 2	K Director Promoter	
Clarification of Response (if Necessa	ary):	
Last Name	First Name	Middle Name
Mitchell	Dean	
Street Address 1	Street Address 2	
11975 El Camino Real, Ste 101		
City	State/Province/Country	ZIP/PostalCode
San Diego	CALIFORNIA	92130

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

La	ist Name	First Name	Middle Name
Smaldone Alsu)	Laurie	
Stree	t Address 1	Street Address 2	
11975 El Camin	no Real, Ste 101		
	City	State/Province/Country	ZIP/PostalCode
San Diego		CALIFORNIA	92130
Relationship:	Executive Officer	X Director Promoter	

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund		Health Care X Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care	Retailing Restaurants Technology Computers Telecommunications Other Technology
Is the issuer registered as an investment company under the Investment Company Act of 1940?		Manufacturing Real Estate Commercial	Travel Airlines & Airports Lodging & Conventions
Yes	No	Construction	Tourism & Travel Services
Other Banking & I	Financial Services	REITS & Finance	Other Travel
Business Services		Residential	Other
Energy		Other Real Estate	
Coal Mining			
Electric Utilities			
Energy Conservati	on		
Environmental Ser	vices		

Oil & Gas

Other Energy

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))

Investment Company Act Section 3(c)

Rule 504 (b)(1)(i)	Section 3(c)(1)	Section 3(c)(9)		
Rule 504 (b)(1)(ii)	Section 3(c)(2)	Section 3(c)(10)		
Rule 504 (b)(1)(iii) X Rule 506(b)	Section 3(c)(3)	Section 3(c)(11)		
Rule 506(c)	Section 3(c)(4)	Section 3(c)(12)		
Securities Act Section 4(a)(5)	Section 3(c)(5)	Section 3(c)(13)		
	Section 3(c)(6)	Section 3(c)(14)		
	Section 3(c	2)(7)			
7. Type of Filing					
New Notice Date of First Sale 2020-07-21 X Amendment	First Sale Yet	to Occur			
8. Duration of Offering					
Does the Issuer intend this offering to last more the	nan one year?	Yes X No			
9. Type(s) of Securities Offered (select all that app	oly)				
X Equity		Pooled In	vestment Fund Interests	5	
Debt			-Common Securities		
Option, Warrant or Other Right to Acquire And Security to be Acquired Upon Exercise of Option Other Right to Acquire Security			roperty Securities scribe)		
10. Business Combination Transaction					
Is this offering being made in connection with a b as a merger, acquisition or exchange offer?	usiness combi	ination transa	ction, such Yes X	No	
Clarification of Response (if Necessary):					
11. Minimum Investment					
Minimum investment accepted from any outside i	nvestor \$0 US	SD			
12. Sales Compensation					
Recipient	Reci	pient CRD N	umber X None		
(Associated) Broker or Dealer X None	(Ass Num	,	ker or Dealer CRD	X None	2
Street Address 1			Street Address 2		
City	State	/Province/Co	untry		ZIP/Postal Code
State(s) of Solicitation (select all that apply)ACheck "All States" or check individualStates	ll Fo tates	reign/non-US	5		
13. Offering and Sales Amounts					
Total Offering Amount \$97,999,937 USD or	Indefinite				
Total Amount Sold \$97,999,937 USD					
Total Remaining to be Sold \$0 USD or	Indefinite				
Clarification of Response (if Necessary):					
14. Investors					

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited

investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

24

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Kinnate Biopharma Inc.	Mark Meltz	Mark Meltz	Chief Operating Officer	2020-08-27

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.